Search

Study on Expression of Urokinase-Type Plasminogen Activator mRNA in Gastric Cancer

Objective To investigate the expression of urokinase-type plasminogen activator (uPA) mRNA in gastric cancer tissues and cancer-adjacent tissues and the relationship between its expression and biologic behavior of tumor. Methods Fourty-eight cases with gastric cancer were detected for the expression of uPA mRNA by fluorogenic probe quantitative reverse transcription polymerase chain reaction (RTPCR). Results The positive expression rate of uPA mRNA was 83.3%, 25.0%, 93.8% and 62.5% in gastric cancer tissues,cancer-adjacent tissues, gastric cancer tissues with lymph node metastasis and with non-lymph node metastasis respectively. Expression of uPA mRNA was positively related with the invasion depth of gastric cancer. Conclusion Expression of uPA mRNA is significantly increased in gastric cancer and it can be used as an indicator to judge the metastasis and prognosis of tumor.

Expression and Pathological Significance of E-Cadherin and Uridylyl Phosphate Adenosine in Breast Carcinoma

目的　探討上皮細胞鈣黏蛋白（E-Cadherin）、尿激酶型纖溶酶原激活劑（uPA）表達與乳腺癌的浸潤、淋巴結轉移的關系。 方法　采用免疫組織化學鏈霉菌抗生物素蛋白-過氧化物酶連接法對乳腺纖維腺瘤、乳腺腺病和乳腺癌各40例蠟塊中E-Cadherin、uPA表達進行研究。 結果　乳腺纖維腺瘤、腺病和乳腺癌中E-Cadherin陽性率分別為85.0%、82.5%和20.0%，三者差異有統計學意義（P＜0.05）；E-Cadherin表達陰性患者淋巴結轉移率（90.6%）高于E-Cadherin表達陽性者（25.0%），差異有統計學意義（P＜0.01）。uPA在乳腺纖維腺瘤、腺病均呈陰性表達，在乳腺癌中的陽性率為60.0%，三者差異有統計學意義（P＜0.05）；uPA表達陽性患者淋巴結轉移率（88.5%）顯著高于陰性者（50.0%），兩者的表達差異有統計學意義（P＜0.05）。 結論　E-Cadherin和uPA的表達與乳腺癌的浸潤轉移密切相關，同步檢測其在乳腺癌組織中的表達并綜合分析二者之間的關系，對評價乳腺癌細胞的侵襲轉移能力及預后判斷具有一定價值。uPA在乳腺癌中表達率較高，而且和乳腺癌的生物學特性有關，它對提示預后和開展靶向治療有指導意義。

Thrombolysis infusion via microcatheter treating central retinal artery occlusion

ObjectiveTo investigate the therapeutic effects of thrombolysis infusion via microcatheter on the treatment of central retinal artery occlusion(CRAO). MethodsUrokinase (UK) was directly infused via ophthalmic artery (OA) by microcatheter (6 patients) or via intravenous (7 patients) to dissolve the thrombus. The patency of the artery was evaluated by fundus fluorescein angiography (FFA), and the effect of fibrinolytic activity on the systemic changes was observed by blood biochemical examination simultaneously. ResultsIn 6 patients in the microcatheter group, 5 had completely and 1 had partly reopened OA on the morrow of UK infusion with the patency rate of 83.33%, while in 7 patients in vein group, 3 completely reopened, 2 partly reopened and 2 obstructed OA were found with the patency rate of 42.86%. The difference between the two groups was significant. No obvious change of index of blood coagulation system was found in catheter group, which had great disparity compared with the vein group.ConclusionUrokinase infusion via microcatheter in CRAO has better therapeutic impact and smaller effect on systemic action. (Chin J Ocul Fundus Dis, 2005,21:16-19)

Study on the Thrombolysis Effect of Urokinase in Different Time Periods of Acute Cerebral Infarction

【摘要】　目的　探討急性腦梗死溶栓治療的療效及安全性。　方法　2004年1月-2009年5月58例急性腦梗死患者，按接受尿激酶治療時已發病時間分為3組，均接受尿激酶150萬U加生理鹽水150 mL靜脈滴注溶栓治療。分別在治療后0、1、3、9 h進行神經功能評價，1、3、7 d進行神經功能評價及復查頭顱CT。　結果　發病3 h內與發病3~6 h內溶栓治療效差異無統計學意義（Pgt;0.05）；發病3 h內、3~6 h內與發病6~9 h尿激酶溶栓治療療效差異均有統計學意義（Plt;0.05）；發病6~9 h尿激酶溶栓治療療效差，多例并發腦出血，安全性差。　結論　發病6 h內的腦梗死患者，只要無禁忌證均應盡快行尿激酶溶栓治療；發病6 h后的腦梗死患者，不宜尿激酶溶栓治療；伴房顫者的溶栓治療因樣本量過小研究無意義，有待進一步研究。【Abstract】　Objective　To discuss the efficacy and safety of thrombolytic therapy for acute cerebral infarction. 　Methods　A total of 58 patients with acute cerebral infarction from January 2004 to May 2009 were enrolled in this study. Based on the onset time before accepting urokinase treatment, the patients were divided into three groups. All of them accepted thrombolytic treatment with 1.5 million U of urokinase and 150 ml of saline solution intravenously. Neurological function evaluation was carried out 0, 1, 3, and 9 hours after the treatment. Another neurological function evaluation and skull CT were done 1, 3, and 7 days later, respectively.　Results　There was no statistical difference between the efficacy of the treatment within 3 hours and between the 3rd hour and the 6th hour after the onset of the disease. However, there was a significant difference between the efficacy within 3 hours and between the 6th and 9th hour, and between the efficacy from the 3rd hour and 6th hour and from the 6th hour and the 9th hour after the onset of the disease. Between the 6th and the 9th hour after the onset, the efficacy and safety were poor with many cases of combined cerebral bleeding.　Conclusions　For patients within 6 hours after the onset of cerebral infarction, as long as no contraindications exists, thrombolytic therapy should be carried out as soon as possible; 6 hours after the onset, patients should not be treated with thrombolytic therapy. Further study is needed for patients combined with atrial fibrillation due to the small sample size in this study.

超選眼動脈插管溶栓治療視網膜中央動脈阻塞一例

尿激酶治療急性缺血性視神經病變初步觀察

目的：評價尿激酶治療急性缺血性視神經病變的療效。 方法：將68例（82只眼）急性缺血性視神經病變隨機分為尿激酶治療組46只眼及對照組36只眼，隨訪期為2個月。 結果：治療組視力改善率93.5%，對照組為52.8%（P＜0.005）. 結論：結果提示尿激酶可能是治療急性缺血性視神經病變的一種更為有效的藥物。 （中華眼底病雜志，1996，12：248-249）

微創胸膜腔置管注入尿激酶治療結核性胸腔積液

【摘要】 目的 探討微創胸膜腔置入中心靜脈導管(簡稱導管)注入尿激酶治療結核性包裹性胸腔積液(簡稱積液)的臨床價值。方法 2008年6月-2009年8月在正規抗結核治療基礎上,選取確診積液患者72例,按數字隨機法分為治療組和對照組,治療組36例經超聲引導導管置入胸膜腔并注入生理鹽水50 mL加尿激酶10萬 U,對照組36例多次穿刺抽液,比較兩組療效及積液引流量、胸膜厚度、積液吸收時間等。結果 治療組28例顯效,5例好轉,3例無效;對照組10例顯效,13例好轉,13例無效,兩組療效差異具有統計學意義(Plt;0.05)。治療組與對照組平均積液引流量分別為1 421 mL和756 mL,胸膜厚度分別為(1.9±0.4) mm和(3.7±1.2) mm,積液吸收時間分別為(13.3±1.2)d和(17.3±1.6)d,兩組間比較差異均有統計學意義(Plt;0.05)。結論 超聲引導導管置入胸膜腔并注入尿激酶治療結核性包裹性胸腔積液療效顯著,可增加引流量,減輕胸膜肥厚,改善肺功能,減少穿刺機會。

Comparison of recombinant staphylokinase and urokinase in the treatment of experimental occlusion of the central retinal artery

Objective To inspect the effects of recombinant staphylokinase (r-Sak) and the changes of fibrinolytic activity in the systemic circulation in the treatment of experimental central retinal artery occlusion (CRAO)． Methods The animal model of CRAO in 15 cats (30 eyes) was set up by laser irradiating a branch of central retinal artery after intravenous injection of 3% rose bengal，and then the arterial thrombi were dissolved by intravenous injection of r-Sak and urokinase (UK)．The pat ency of the arteries was evaluated by FFA．Moreover，the changes of fibrinolitic activity in the blood were examined by phlebotomizing． Results The model of CRAO was successfully set up.Four hours after injection of thrombolysis drugs,the completely reopened proportion in r-Sak group was 100%，while in UK group the proportion was 60%．At the same time， no significant systemic fibinnolytic activation was observed in r-Sak group． Conclusions An experimental CRAO model,which has the similar pathological processes of occlusion of central retinal artery and intra arterial thrombosis as those in clinic，can be set up by using photochemical method，and r-rak is capable of lysing thrombus without significant activation of circulating plasminogen． (Chin J Ocul Fundus Dis，2000，16：71-138)

急性腦梗死尿激酶溶栓治療后血清尿酸水平變化與梗死體積及神經功能缺損關系

目的　分析急性腦梗死患者溶栓治療后尿酸水平變化與梗死體積及神經功能缺損的關系。 方法　選取2006年2月－2011年3月急性腦梗死患者59例，按梗死體積分為小梗死組（≤5 cm3），大梗死組（＞5 cm3）；根據神經功能缺損程度評分分為輕度損傷組（0～12分），重度損傷組（≥13分），比較不同梗死體積和損傷程度時溶栓前后尿酸水平變化。 結果　尿激酶溶栓治療后重度損傷組患者較輕度損傷組發病第2天尿酸水平下降顯著，差異有統計學意義（P＜0.05）；不同梗死體積尿酸水平變化不同，大梗死組尿激酶溶栓治療后較小梗死組發病第2天尿酸水平明顯下降，兩組間溶栓第2天尿酸水平，差異具有統計學意義（P＜0.05）。 結論　急性腦梗死溶栓后尿酸水平下降，梗死體積越大者尿酸水平下降越顯著；同時神經功能缺損程度越高者尿酸水平下降越明顯。尿酸在缺血再灌注過程中發揮一定作用，尿酸水平變化與腦梗死體積及神經功能缺損程度有關。

超選眼動脈溶栓治療視網膜中央動脈阻塞